COLLECTING DUCT CARCINOMA
Clinical trials for COLLECTING DUCT CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new COLLECTING DUCT CARCINOMA trials appear
Sign up with your email to follow new studies for COLLECTING DUCT CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Matched conditions: COLLECTING DUCT CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 08:00 UTC
-
New combo therapy targets rare, aggressive kidney tumors
Disease control Recruiting nowThis phase 2 trial is testing two drugs—pembrolizumab (Keytruda) and enfortumab vedotin (Padcev)—in people with rare kidney cancers called collecting duct carcinoma and renal medullary carcinoma. About 23 patients with advanced or metastatic disease will receive the combination f…
Matched conditions: COLLECTING DUCT CARCINOMA
Phase: PHASE2 • Sponsor: Giuseppe Procopio • Aim: Disease control
Last updated Jun 26, 2026 15:17 UTC